Jazz Pharmaceuticals plc

146.49+3.68+2.58%Vol 412.96K1Y Perf -19.84%
May 13th, 2022 16:00 DELAYED
BID145.04 ASK148.23
Open144.57 Previous Close142.81
Pre-Market145.50 After-Market-
 -0.99 -0.68%  - -
Target Price
203.67 
Analyst Rating
Strong Buy 1.33
Potential %
39.03 
Finscreener Ranking
★★     45.69
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     44.71
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
     38.35
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
40.43 
Earnings Rating
Strong Buy
Market Cap9.13B 
Earnings Date
4th May 2022
Alpha-0.00 Standard Deviation0.09
Beta0.79 

Today's Price Range

144.11148.89

52W Range

117.64189.00

5 Year PE Ratio Range

9.5044.70

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-4.03%
1 Month
-12.41%
3 Months
2.94%
6 Months
4.99%
1 Year
-19.84%
3 Years
7.48%
5 Years
-4.75%
10 Years
206.02%

TickerPriceChg.Chg.%
JAZZ146.493.68002.58
AAPL147.114.55003.19
GOOG2 330.3167.09002.96
MSFT261.125.77002.26
XOM88.862.56002.97
WFC42.640.83001.99
JNJ176.85-1.0200-0.57
FB198.627.38003.86
GE75.051.77002.42
JPM119.091.05000.89
Financial StrengthValueIndustryS&P 500US Markets
1.40
3.40
0.63
1.70
0.20
Leverage Ratio 3.20
ProfitabilityValueIndustryS&P 500US Markets
84.40
2.40
22.40
16.60
-13.25
RevenueValueIndustryS&P 500US Markets
3.30B
52.96
15.75
14.89
Earnings HistoryEstimateReportedSurprise %
Q01 20223.003.134.33
Q04 20212.983.6622.82
Q03 20212.603.6440.00
Q02 20212.923.2912.67
Q01 20213.093.4210.68
Q04 20203.583.56-0.56
Q03 20203.533.869.35
Q02 20202.963.2610.14
Earnings Per EndEstimateRevision %Trend
6/2022 QR3.768.67Positive
9/2022 QR3.64-0.55Negative
12/2022 FY13.55-4.04Negative
12/2023 FY14.64--
Next Report Date-
Estimated EPS Next Report3.00
Estimates Count8
EPS Growth Next 5 Years %8.20
Volume Overview
Volume412.96K
Shares Outstanding62.32K
Shares Float54.35M
Trades Count12.87K
Dollar Volume60.64M
Avg. Volume598.99K
Avg. Weekly Volume625.23K
Avg. Monthly Volume583.53K
Avg. Quarterly Volume588.22K

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) stock closed at 146.49 per share at the end of the most recent trading day (a 2.58% change compared to the prior day closing price) with a volume of 412.96K shares and market capitalization of 9.13B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1940 people. Jazz Pharmaceuticals plc CEO is Bruce C. Cozadd.

The one-year performance of Jazz Pharmaceuticals plc stock is -19.84%, while year-to-date (YTD) performance is 14.98%. JAZZ stock has a five-year performance of -4.75%. Its 52-week range is between 117.64 and 189, which gives JAZZ stock a 52-week price range ratio of 40.43%

Jazz Pharmaceuticals plc currently has a PE ratio of -20.40, a price-to-book (PB) ratio of 2.64, a price-to-sale (PS) ratio of 2.68, a price to cashflow ratio of 13.30, a PEG ratio of 2.32, a ROA of -4.96%, a ROC of -3.25% and a ROE of -12.51%. The company’s profit margin is -13.25%, its EBITDA margin is 22.40%, and its revenue ttm is $3.30 Billion , which makes it $52.96 revenue per share.

Of the last four earnings reports from Jazz Pharmaceuticals plc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $3.00 for the next earnings report. Jazz Pharmaceuticals plc’s next earnings report date is -.

The consensus rating of Wall Street analysts for Jazz Pharmaceuticals plc is Strong Buy (1.33), with a target price of $203.67, which is +39.03% compared to the current price. The earnings rating for Jazz Pharmaceuticals plc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Jazz Pharmaceuticals plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Jazz Pharmaceuticals plc has a Sell technical analysis rating based on Technical Indicators (ADX : 9.56, ATR14 : 5.92, CCI20 : -96.81, Chaikin Money Flow : -0.07, MACD : -4.16, Money Flow Index : 8.61, ROC : -9.92, RSI : 37.14, STOCH (14,3) : 29.47, STOCH RSI : 0.94, UO : 40.04, Williams %R : -70.53), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Jazz Pharmaceuticals plc in the last 12-months were: Bruce C. Cozadd (Option Excercise at a value of $3 834 361), Bruce C. Cozadd (Sold 66 598 shares of value $9 500 614 ), Catherine A. Sohn (Sold 1 306 shares of value $193 236 ), Elmar Schnee (Sold 1 632 shares of value $251 328 ), Heather Ann McSharry (Sold 1 414 shares of value $209 215 ), Jennifer Cook (Sold 417 shares of value $50 582 ), Kenneth W. O'Keefe (Sold 1 306 shares of value $193 236 ), Kim Sablich (Sold 2 748 shares of value $371 000 ), Neena M. Patil (Sold 296 shares of value $45 559 ), Norbert G. Riedel (Sold 1 306 shares of value $193 236 ), Patricia Carr (Sold 314 shares of value $46 459 ), Paul L. Berns (Sold 1 450 shares of value $223 300 ), Peter P. Gray (Sold 1 414 shares of value $209 215 ), Rick E. Winningham (Sold 1 306 shares of value $193 236 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
12 (80.00 %)
12 (80.00 %)
11 (84.62 %)
Moderate Buy
1 (6.67 %)
1 (6.67 %)
1 (7.69 %)
Hold
2 (13.33 %)
2 (13.33 %)
1 (7.69 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.33
Strong Buy
1.23

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.

CEO: Bruce C. Cozadd

Telephone: +353 16347800

Address: Waterloo Road, Dublin D04 E5W7, , IE

Number of employees: 1 940

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

75%25%

Bearish Bullish

58%42%

Bearish Bullish

57%43%

Bearish Bullish

55%45%

TipRanks News for JAZZ

Thu, 05 May 2022 12:27 GMT Jazz Pharmaceuticals (JAZZ) Gets a Buy Rating from Jefferies

- TipRanks. All rights reserved.

Tue, 26 Apr 2022 12:38 GMT Jazz Pharmaceuticals (JAZZ) Gets a Buy Rating from Needham

- TipRanks. All rights reserved.

Fri, 08 Apr 2022 01:47 GMT Jazz Pharmaceuticals (JAZZ) Gets a Buy Rating from RBC Capital

- TipRanks. All rights reserved.

Thu, 07 Apr 2022 13:15 GMT Jazz Pharmaceuticals (JAZZ) Receives a Buy from Needham

- TipRanks. All rights reserved.

Mon, 07 Feb 2022 11:16 GMT Jazz Pharmaceuticals (JAZZ) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits